Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419263 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 344
- Enrollment target
NCT00419263 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 344 participants.
The verdict
NCT00419263, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 344 participants
- Enrollment target
Study Summary
This is a study for patients with flu who also have a fever as well as other flu symptoms. Patients must have had symptoms for less than 48 hours in order to participate. Patients will have two out of three chances of getting an active study treatment and the other third will receive a placebo (dummy drug). Nobody will know who gets the active drug and who gets the inactive drug. All patients will get supplies to treat symptoms of flu. Patients will need to be seen 5 more times after they are enrolled in the study.
Interventions
- DRUG Placebo
- DRUG Peramivir 150 mg
- DRUG Peramivir 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419263
The ClinicalTrials.gov registry entry for NCT00419263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00419263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419263 about?
NCT00419263 is a clinical study titled "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.". This is a study for patients with flu who also have a fever as well as other flu symptoms. Patients must have had symptoms for less than 48 hours in order to participate. Patients will have two out of three chances of getting an active study treatment and the other third will receive a placebo (dumm...
What is the current status of trial NCT00419263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 344 participants. The study started on 2007-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00419263?
The interventions under investigation include: Placebo (DRUG), Peramivir 150 mg (DRUG), Peramivir 300 mg (DRUG).
Who is sponsoring clinical trial NCT00419263?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.